跳至主要内容
临床试验/NL-OMON55240
NL-OMON55240已完成不适用

Faecal Metabolomics and Microbiota as Non-Invasive Biomarkers for Disease Activity and to Predict Treatment Response in Paediatric Inflammatory Bowel Disease - Biomarkers for Disease Activity and Therapy Response in paediatric IBD

Academisch Medisch Centrum0 个研究点目标入组 185 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
185

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
2 至 17(—)

入选标准

  • - Age of 4-17 years
  • - New patients with a suspicion of IBD or patients with gastrointestinal
  • symptoms who undergo diagnostic work-up (including clinical, laboratory and
  • faecal markers but not necessarily endoscopy) to exclude IBD may be recruited.
  • If a diagnosis is not confirmed after the investigations are complete they will
  • not be followed up any further but any specimens and clinical information can
  • be retained as controls
  • - Written informed consent
  • - Patients have not started IBD treatment yet

排除标准

  • - Use of antibiotics or probiotics in the last 3 months prior to inclusion
  • - Use of immunosuppressive therapy prior to the study
  • - Patients diagnosed with immunocompromised disease (any of various diseases
  • that suppress the immune system)
  • - Inability to read and understand the patient and family information sheets
  • (for example insufficient knowledge of national language, where no health
  • advocate of family member is available to translate and ensure full
  • understanding of the study)
  • - Informed consent of patient and/or parents has not been obtained when

研究者

相似试验